Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

Doozio Jun. 27 at 3:25 PM

$RLMD it’s only obvious wen it’s obvious ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 27 at 3:24 PM

$RLMD da 🐑 are SKWD again as da rotation ONTA semis ENTA biotechs out of the tightness 🐒🍌🧠⏰♾️

0 · Reply

SannieVerraderlijk Jun. 19 at 5:58 AM

$ABOS $CCCC $NKTR $RLMD $ SABS $ ZURA Some longs added to Russell 3000 yesterday

0 · Reply

Eathapoo Jun. 16 at 5:05 PM

$VTGN hoping for the best here. I made the mistake selling $RLMD for $0.60 and then 💥. Holding strong. Let go $5.

0 · Reply

PLATINUM_TRADES Jun. 10 at 1:48 PM

$RLMD $6.56 Broke.. $6.80 Next major resistance... Who loves June 🥇🥇

0 · Reply

PLATINUM_TRADES Jun. 10 at 1:39 PM

$RLMD Another overnight swing winner 🥇🥇. $6.56 Still possible imo🚨🚨

0 · Reply

PLATINUM_TRADES Jun. 10 at 11:46 AM

$RLMD $RLMD adds! $6.56 Next major resistance 🚨 🚨

0 · Reply

teaman60 Jun. 2 at 4:53 PM

$RLMD Looks like maybe some bad test results have leaked

2 · Reply

YushimiCloud Jun. 2 at 9:54 AM

$RLMD Strong Phase 2 efficacy for NDV-01.,

0 · Reply

ThaDankles May. 22 at 10:13 PM

$RLMD $VTGN will be bigger than RLMD and more explosive. 1/3 the float and if phase 3 is positive then we have the only rapid a response non habit forming anti anxiety drug on the market…. Cmon a nasal spray. Hell I’d want a script for that! Huge market for that! 50$ on commercialization if it makes it that far before a buy out.

1 · Reply

Relmada Therapeutics initiated with a Buy at H.C. Wainwright

Jun 11, 2026, 7:00 AM EDT - 17 days ago

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Jun 9, 2026, 7:00 AM EDT - 19 days ago

Relmada Therapeutics Slides: Corporate presentation

Jun 4, 2026, 12:50 PM EDT - 24 days ago

Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 7:00 AM EDT - 4 weeks ago

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2026, 9:30 AM EDT - 4 weeks ago

Relmada Therapeutics Transcript: AGM 2026

2026-05-13T21:24:00.000Z - 6 weeks ago

Relmada Therapeutics files automatic mixed securities shelf

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Relmada Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Relmada Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Relmada Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:05 PM EDT - 6 weeks ago

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Relmada Therapeutics Slides: Company presentation

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Relmada Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 7 weeks ago

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Relmada Therapeutics Registration statement: Registration filing

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Slides: Corporate presentation

2026-03-24T09:00:12.000Z - 3 months ago

Relmada Therapeutics initiated with an Overweight at Piper Sandler

2026-03-20T11:37:53.000Z - 3 months ago

Relmada Therapeutics price target raised to $19 from $10 at Mizuho

Mar 19, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics Earnings Call Transcript: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics Annual report: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 4:01 PM EDT - 3 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Mar 19, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Slides: Study Result Presentation

Mar 19, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Slides: Corporate presentation

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 10, 2026, 8:40 AM EDT - 3 months ago

Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

2026-03-09T12:00:38.000Z - 3 months ago

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

2026-03-09T11:30:59.000Z - 3 months ago

Relmada Therapeutics prices 29.47M shares at $4.75 in private placement

2026-03-09T11:15:52.000Z - 3 months ago

Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01

Mar 9, 2026, 7:05 AM EDT - 3 months ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

2026-03-02T11:38:48.000Z - 4 months ago

Relmada Therapeutics initiated with a Buy at Lucid Capital

2026-01-23T11:25:12.000Z - 5 months ago

Relmada Therapeutics assumed at Outperform from Market Perform at Leerink

2026-01-12T12:16:48.000Z - 5 months ago

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

Jan 12, 2026, 7:00 AM EST - 5 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

2025-12-22T00:10:11.000Z - 6 months ago

Relmada Therapeutics initiated with a Buy at Jefferies

2025-12-03T12:35:52.000Z - 7 months ago

Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting

Dec 3, 2025, 7:30 AM EST - 7 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

2025-11-19T13:40:55.000Z - 7 months ago

Mizuho upgrades Relmada to Outperform with ‘more upside’ ahead

2025-11-19T13:35:38.000Z - 7 months ago

Relmada Therapeutics upgraded to Outperform from Neutral at Mizuho

Nov 14, 2025, 6:00 AM EST - 8 months ago

Relmada Therapeutics Slides: Investor presentation

Nov 13, 2025, 4:30 PM EST - 8 months ago

Relmada Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Relmada Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Relmada Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:01 PM EST - 8 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 8 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

2025-11-04T12:50:53.000Z - 8 months ago

Relmada Therapeutics announces FDA feedback on study paths for NDV-01

2025-11-04T12:50:30.000Z - 8 months ago

Relmada Therapeutics prices 40.1M shares at $2.20 in underwritten offering

Nov 4, 2025, 7:09 AM EST - 8 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 8 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

2025-10-07T11:41:16.000Z - 9 months ago

Relmada Therapeutics appoints Max Kates to clincal advisory board

Oct 7, 2025, 7:30 AM EDT - 9 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 18, 2025, 10:00 AM EDT - 10 months ago

Relmada Therapeutics Transcript: Small-Cap Virtual Conference

Sep 16, 2025, 9:00 AM EDT - 10 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 10 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Relmada Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Relmada Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Relmada Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 11 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 1 year ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Transcript: Status Update

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Press release: Status Update

Apr 28, 2025, 1:38 PM EDT - 1 year ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 1 year ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 20, 2024, 7:00 AM EST - 1 year ago

Relmada Therapeutics Transcript: Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Quarterly report: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Registration statement: Registration Filing

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 4:05 PM EDT - 2 years ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 2 years ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Doozio Jun. 27 at 3:25 PM

$RLMD it’s only obvious wen it’s obvious ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jun. 27 at 3:24 PM

$RLMD da 🐑 are SKWD again as da rotation ONTA semis ENTA biotechs out of the tightness 🐒🍌🧠⏰♾️

0 · Reply

SannieVerraderlijk Jun. 19 at 5:58 AM

$ABOS $CCCC $NKTR $RLMD $ SABS $ ZURA Some longs added to Russell 3000 yesterday

0 · Reply

Eathapoo Jun. 16 at 5:05 PM

$VTGN hoping for the best here. I made the mistake selling $RLMD for $0.60 and then 💥. Holding strong. Let go $5.

0 · Reply

PLATINUM_TRADES Jun. 10 at 1:48 PM

$RLMD $6.56 Broke.. $6.80 Next major resistance... Who loves June 🥇🥇

0 · Reply

PLATINUM_TRADES Jun. 10 at 1:39 PM

$RLMD Another overnight swing winner 🥇🥇. $6.56 Still possible imo🚨🚨

0 · Reply

PLATINUM_TRADES Jun. 10 at 11:46 AM

$RLMD $RLMD adds! $6.56 Next major resistance 🚨 🚨

0 · Reply

teaman60 Jun. 2 at 4:53 PM

$RLMD Looks like maybe some bad test results have leaked

2 · Reply

YushimiCloud Jun. 2 at 9:54 AM

$RLMD Strong Phase 2 efficacy for NDV-01.,

0 · Reply

ThaDankles May. 22 at 10:13 PM

1 · Reply

Eathapoo May. 22 at 11:34 AM

$VTGN I recall selling $RLMD at $0.60 then look what happened. Not making that mistake again with $VTGN happy Friday. Stay focus.

0 · Reply

VikaDelic May. 20 at 3:41 PM

$RLMD now the number 3 holding in the psychedelics ETF (PSIL). PSIL will need to rebalance a bit at some point, which aligns directly with us being pinned near $7 and the chart showing steady background accumulation. Otherwise it’s insider buys and a steady run up until now. Whether you like it or not, we are tied to the movement of psychedelics going into their massive catalyst period over next 2-3 months. This could run substantially, unrelated to their cancer drug that works. Two giant irons in the fire 🔥

0 · Reply

teaman60 May. 18 at 7:31 PM

$RLMD This is the first time a stop loss actually saved me money. Something fishy

1 · Reply

teaman60 May. 18 at 5:10 PM

$RLMD Whoops, something bad happened

0 · Reply

SuperGreenToday May. 15 at 5:41 AM

$RLMD Share Price: $7.43 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $0.94 – $1.16 Target Zone: $1.73 – $2.11 Potential Upside: 73% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MarketBeat May. 13 at 2:08 AM

https://marketbeat.com/a/8651231/ $RLMD Relmada Therapeutics Q1 Earnings Call Highlights

0 · Reply

teaman60 May. 12 at 11:56 PM

$RLMD Unknown, unfollowed company with superior drugs in its pipeline.

1 · Reply

EarningsInsider May. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript

0 · Reply

StocktwitsEarnings May. 12 at 9:09 PM

$RLMD Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.22 up 62.07% YoY • Relmada Therapeutics expects its $234.0 million cash balance as of March 31, 2026, to fund operations through 2029, including NDV-01 Phase 3 completion, and is on track to initiate the Phase 3 program in mid-2026.

0 · Reply

teaman60 Apr. 27 at 3:18 PM

$RLMD Gas a real problem with being over $7

2 · Reply

teaman60 Apr. 21 at 2:13 PM

$RLMD Someone dumping shares today. They are doing it slowly to get the most they can.

0 · Reply

teaman60 Apr. 21 at 1:45 PM

$RLMD Rug pull? If trials go bad this is gone.

0 · Reply

Market Cap	701.71M
Revenue (ttm)	0.00
Net Income (ttm)	-57.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	15,605,199
Avg Vol	1,595,444
Day's Range	N/A - N/A
Shares Out	104.89M
Stochastic %K	49%
Beta	0.39
Analysts	Strong Sell
Price Target	$12.67